Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/13/2020 01/14/2020 01/15/2020 01/16/2020 01/17/2020 Date
85.12(c) 85.74(c) 87.38(c) 88.28(c) 89(c) Last
5 571 496 8 751 380 5 389 727 5 023 287 5 879 746 Volume
-0.28% +0.73% +1.91% +1.03% +0.82% Change
More quotes
Financials (USD)
Sales 2019 31 846 M
EBIT 2019 7 149 M
Net income 2019 3 655 M
Debt 2019 13 045 M
Yield 2019 1,43%
Sales 2020 33 956 M
EBIT 2020 7 893 M
Net income 2020 4 482 M
Debt 2020 6 262 M
Yield 2020 1,57%
P/E ratio 2019 42,5x
P/E ratio 2020 35,1x
EV / Sales2019 5,35x
EV / Sales2020 4,82x
Capitalization 157 B
More Financials
Company
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - vascular devices (30.9%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - diagnostic... 
More about the company
Surperformance© ratings of Abbott Laboratories
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBOTT LABORATORIES
01/18Change of Company Secretary of Abbott Laboratories Limited
AQ
01/18Appointment of Company Secretary of Abbott Laboratories Limited
AQ
01/17ABBOTT LABORATORIES : annual earnings release
01/15ABBOTT LABORATORIES : To initiate trial to study mitraclip as an option for mode..
AQ
01/14ABBOTT LABORATORIES : Ex-dividend day for
FA
01/13Bigfoot Biomedical Gets $45 Million of Financing Led by Abbott Labs
DJ
01/13ABBOTT : to Initiate Trial to Study MitraClip as an Option for Moderate Surgical..
PR
01/08ABBOTT LABORATORIES : Labs Appoints CFO on the Heels of New CEO Hire
DJ
01/08ABBOTT LABORATORIES : Appoints Funck as Finance Chief; Yoor to Retire
DJ
01/08ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
01/07ABBOTT : FDA Approves Less Invasive Surgical Approach for Heart Pump
DJ
01/07ABBOTT LABORATORIES : FDA Approves Less Invasive Surgical Approach for Abbott's ..
PR
01/02ABBOTT : Hosts Conference Call for Fourth-Quarter Earnings
PR
2019ABBOTT LABORATORIES : Termination of a Material Definitive Agreement, Triggering..
AQ
2019Boeing’s woes have huge repercussions
More news
News in other languages on ABBOTT LABORATORIES
01/20STOCK MARKET PARIS : Une semaine chargée en perspective
01/17AVIS D'ANALYSTES DU JOUR : Alstom, Nexans, Publicis, Edenred, Ubisoft, Sodexo, N..
01/17STOCK MARKET PARIS : Vers l'infini, et au-delà ?
01/17ABBOTT LABORATORIES : Veröffentlichung des Jahresergebnisses
01/17ABBOTT LABORATORIES : publication des résultats annuels
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Sector news : Medical Equipment
02:48aCREDIT MARKETS : European Bonds Draw In U.S. Companies -- WSJ
DJ
01/20Europe's Cheap Debt Draws Record Borrowing by U.S. Companies
DJ
01/20Japan's Maeda Corp to launch unsolicited bid to buy a road paving company
RE
01/17Health Executives Brace for Change In Regulation and Competition -- WSJ
DJ
01/17Toshiba succeeds in bid for chip equipment unit, beating Hoya
RE
More sector news : Medical Equipment
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 95,29  $
Last Close Price 89,00  $
Spread / Highest target 23,6%
Spread / Average Target 7,07%
Spread / Lowest Target -19,1%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President & Chief Operating Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES2.46%157 393
NOVOCURE LIMITED9.86%9 163
MASIMO CORPORATION7.39%9 052
ASAHI INTECC CO., LTD.0.00%7 458
PENUMBRA, INC.-2.38%5 599
GETINGE3.22%5 139